Now Available: PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, "PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue...
View full press release